© 2020 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2020 MJH Life Sciences™ and Formulary Watch. All rights reserved.
September 22, 2020
Some of the top medications were approved this summer, while others are awaiting FDA approval.
Both recalls are due to sub-potency of drugs that treat hypothyroidism.
September 15, 2020
The top-selling diabetes drug will join semaglutide (Ozempic), which is approved to reduce the risk of major adverse cardiovascular events.
September 14, 2020
The treatment is the first anti-PD-1 antibody from China to receive Breakthrough therapy designation.
September 08, 2020
Pharma makers expect the treatment to be available within a week.
The medication boasts a statistically significant improvement in overall survival versus placebo.
August 31, 2020
One study questions the effectiveness of remdesivir past day 10 while others support its expanded use.
August 28, 2020
The pharma maker will initially produce 150 million of the 5-minute tests.
August 18, 2020
Drug for a specific Duchenne muscular dystrophy mutation is only the second drug approved for the mutation.
August 17, 2020
The drug’s indication for marginal zone lymphoma (MZL) may not be approved until February 2021.